EMAIL THIS PAGE TO A FRIEND

Brain : a journal of neurology

Connexin-43 induces chemokine release from spinal cord astrocytes to maintain late-phase neuropathic pain in mice.


PMID 24919967

Abstract

Accumulating evidence suggests that spinal cord astrocytes play an important role in neuropathic pain sensitization by releasing astrocytic mediators (e.g. cytokines, chemokines and growth factors). However, it remains unclear how astrocytes control the release of astrocytic mediators and sustain late-phase neuropathic pain. Astrocytic connexin-43 (now known as GJ1) has been implicated in gap junction and hemichannel communication of cytosolic contents through the glial syncytia and to the extracellular space, respectively. Connexin-43 also plays an essential role in facilitating the development of neuropathic pain, yet the mechanism for this contribution remains unknown. In this study, we investigated whether nerve injury could upregulate connexin-43 to sustain late-phase neuropathic pain by releasing chemokine from spinal astrocytes. Chronic constriction injury elicited a persistent upregulation of connexin-43 in spinal astrocytes for >3 weeks. Spinal (intrathecal) injection of carbenoxolone (a non-selective hemichannel blocker) and selective connexin-43 blockers (connexin-43 mimetic peptides (43)Gap26 and (37,43)Gap27), as well as astroglial toxin but not microglial inhibitors, given 3 weeks after nerve injury, effectively reduced mechanical allodynia, a cardinal feature of late-phase neuropathic pain. In cultured astrocytes, TNF-α elicited marked release of the chemokine CXCL1, and the release was blocked by carbenoxolone, Gap26/Gap27, and connexin-43 small interfering RNA. TNF-α also increased connexin-43 expression and hemichannel activity, but not gap junction communication in astrocyte cultures prepared from cortices and spinal cords. Spinal injection of TNF-α-activated astrocytes was sufficient to induce persistent mechanical allodynia, and this allodynia was suppressed by CXCL1 neutralization, CXCL1 receptor (CXCR2) antagonist, and pretreatment of astrocytes with connexin-43 small interfering RNA. Furthermore, nerve injury persistently increased excitatory synaptic transmission (spontaneous excitatory postsynaptic currents) in spinal lamina IIo nociceptive synapses in the late phase, and this increase was suppressed by carbenoxolone and Gap27, and recapitulated by CXCL1. Together, our findings demonstrate a novel mechanism of astrocytic connexin-43 to enhance spinal cord synaptic transmission and maintain neuropathic pain in the late-phase via releasing chemokines.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2502034
Anti-Cxcr2 (N-terminal) antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1406027
Anti-CXCR2 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB2900183
Anti-CXCR2 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB1300019
Anti-FGFR4 (N-term) antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
SAB1300886
Anti-FGFR4 antibody produced in rabbit, saturated ammonium sulfate (SAS) precipitated, buffered aqueous solution
HPA027273
Anti-FGFR4 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, ab1
HPA027369
Anti-FGFR4 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, ab2
HPA028251
Anti-FGFR4 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution, ab3
SAB4300637
Anti-FGFR4 antibody produced in rabbit, affinity isolated antibody
SAB2500462
Anti-GFAP antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1405864
Anti-GFAP antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB4300647
Anti-GFAP antibody produced in rabbit, affinity isolated antibody
HPA056030
Anti-GFAP antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2107063
Anti-GFAP antibody produced in rabbit, affinity isolated antibody
SAB2103792
Anti-IL8RB, (N-terminal) antibody produced in rabbit, affinity isolated antibody
HPA030790
Anti-RBFOX3 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
RAB0054
Human MCP-1 / CCL2 ELISA Kit, for serum, plasma, cell culture supernatant and urine
02685
Lithium atomic spectroscopy standard concentrate 1.00 g Li, for 1 l standard solution, 1.00 g/L, analytical standard
ClLi
746460
Lithium chloride, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
ClLi
793620
Lithium chloride, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, 99%
ClLi
L4408
Lithium chloride, BioXtra, ≥99.0% (titration)
ClLi
62476
Lithium chloride, BioUltra, for molecular biology, anhydrous, ≥99.0% (AT)
ClLi
L9650
Lithium chloride, for molecular biology, ≥99%
ClLi
429457
Lithium chloride, anhydrous, beads, −10 mesh, 99.998% trace metals basis
ClLi
449881
Lithium chloride, anhydrous, beads, −10 mesh, ≥99.9% trace metals basis
ClLi
203637
Lithium chloride, powder, ≥99.99% trace metals basis
ClLi
HT-LICLSLUG
Lithium chloride, anhydrous, chunks, 99.99% trace metals basis
ClLi
751898
Lithium chloride, anhydrous, chunks, 99.99% trace metals basis
ClLi
L7026
Lithium chloride solution, 8 M, for molecular biology, ≥99%
ClLi
694576
Lithium chloride solution, 1 M in 1,3-dimethyl-2-imidazolidinone
ClLi